Chimerix, Inc. (NASDAQ:CMRX) will release its earnings data before the market opens on Monday, November 6th. Analysts expect Chimerix to post earnings of ($0.43) per share for the quarter.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.05. The business had revenue of $0.68 million for the quarter, compared to the consensus estimate of $1.28 million. Chimerix had a negative net margin of 1,514.27% and a negative return on equity of 24.68%. On average, analysts expect Chimerix to post $-1.68 EPS for the current fiscal year and $-1.85 EPS for the next fiscal year.

Chimerix, Inc. (NASDAQ:CMRX) opened at 4.90 on Monday. The stock’s market cap is $230.53 million. The company’s 50 day moving average is $5.13 and its 200 day moving average is $5.07. Chimerix, Inc. has a 52 week low of $3.66 and a 52 week high of $6.64.

Several research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Chimerix from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a research report on Wednesday, August 9th. ValuEngine downgraded shares of Chimerix from a “hold” rating to a “sell” rating in a research report on Friday, August 11th.

ILLEGAL ACTIVITY WARNING: “Chimerix, Inc. (CMRX) Set to Announce Earnings on Monday” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/30/chimerix-inc-cmrx-set-to-announce-earnings-on-monday.html.

Chimerix Company Profile

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

Earnings History for Chimerix (NASDAQ:CMRX)

Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.